Zimbabwe has turned down a substantial American healthcare agreement worth 367 million US dollars (272 million pounds) spanning five years due to Washington's demand for sensitive data.
The decision was revealed after a internal memorandum dated December was disclosed, which showed Head of State Emmerson Mnangagwa believed the agreement was "lopsided".
A government spokesman later clarified that the US was seeking genetic material for scientific study and profit but was unwilling to share the resulting advantages from any future vaccines.
"We will now turn to the difficult and regrettable task of scaling back our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had provided over $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has appealed for further talks to find a deal agreeable to both sides so the country's critical HIV programme can be sustained.
Wider Background
This development follows a similar situation in Kenya, where a court halted a related deal with the US following legal challenges were raised about the security of Kenyans' health data.
After resuming office recently, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
USAID had administered assistance for the US government, but Trump claimed its spending was "inefficient" and his administration was seeking government-to-government deals to enhance openness and responsibility.
As per statements, 16 nations in Africa have to date signed similar health pacts, constituting more than $18.3bn in new funding.
Details of the Rejected Deal
The funds for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration might have yielded significant benefits for the people of Zimbabwe, especially the 1.2 million presently receiving antiretroviral therapy through US-supported programmes," the Ambassador said.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to share its biological resources and data over an extended period, with no equivalent assurance of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"In essence, our nation would supply the basic resources for medical research with no certainty that the end products would be accessible to our people should a future disease outbreak emerge."
Sovereignty and Global Health
Mangwana further pointed out that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were disrupting systems previously established via the global organization.
Mangwana cited its Pathogen Access and Benefit Sharing system designed to deal with future pandemics.
"This system is designed to guarantee that when a nation provides its data, the benefits – such as medicines and cures – are distributed fairly, not commercialised solely by those with the resources to develop them."
These objections regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We welcome continued discussions with our American counterparts on how future co-operation might be structured in a way that honours the sovereignty and interests of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but recommended that negotiations must proceed since a large portion of the nation's HIV programmes relied on external financing.
"Where specific concerns exist, including those involving information security or agreement terms, these can frequently be resolved through detailed discussion and mutually agreed protections," it added.
This impasse emphasises the continuing challenges between accepting vital international aid and safeguarding national sovereignty in an ever more data-driven world.